Marvel Biosciences Corp (TSXV:MRVL) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of units Closed: C$1.6M raised · C$0.15 a unit · 1 warrant at C$0.2 for 12 months · Raymond James Ltd. +5 Dealers: Raymond James Ltd. (finder), Canaccord Genuity Corp. (finder), Research Capital Corporation (finder), Acumen Capital Finance Partners Limited (finder), Hampton Securities (finder), Leede Financial Inc. (finder) Use of proceeds: Deposit for phase 1 clinical trials of lead compound MB-204, general and administrative expenses and general working capital | Sep 29, 2026 | US$1.13M |
| Unsecured convertible debentures Closed: C$500,000 raised · C$0.17 · free to trade Aug 17, 2026 Use of proceeds: Drug formulation, toxicology studies and general working capital | Apr 17, 2026 | US$365,738 |
| Warrant exercise of common share purchase warrants Announced: Warrants at C$0.15 | Oct 3, 2025 | |
| Private placement of units Closed: C$1.02M raised · C$0.125 a unit · 1 warrant at C$0.175 for 24 months · Raymond James Ltd. +5 Dealers: Raymond James Ltd. (finder), Canaccord Genuity Corp. (finder), Acumen Capital Finance Partners Limited (finder), Wood Gundy (finder), Abinvest Corporation (finder), Abingdon Capital Corp. (finder) Use of proceeds: Drug formulation, toxicology studies and general working capital | May 12, 2025 | |
| Private placement of common shares Cancelled: C$1.94M–C$2.5M · C$0.15 a share · Abingdon Capital Dealers: Abingdon Capital (finder) Use of proceeds: Deposit for phase 1 clinical trials of lead compound MB-204, general and administrative expenses and general working capital | May 2, 2025 | US$1.35M |